Lifetime Outcomes of Anti–Vascular Endothelial Growth Factor
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Neovascular age-related macular degeneration (nAMD), the largest single cause of irreversible severe vision loss in high-income countries, can now be treated with vascular endothelial growth factor (VEGF) inhibitors, but to our knowledge, no data on lifetime outcomes are available. The aim of this study was to determine visual acuity (VA) outcomes of anti-vascular endothelial growth factor treatment for nAMD in both eyes for patients’ remaining lifetime.

For the mean remaining lifetime of 11 years, an estimated 12% of the sample retained driving visual acuity, and an estimated 15% reading visual acuity in at least 1 eye. At that time, an estimated 82% of the sample had dropped out. Younger age at baseline and more injections during the first year of treatment were associated with better long-term outcomes. Visual acuity in both eyes over the remaining lifetime.

Anti-vascular endothelial growth factor treatment was associated with preserved useful visual acuity in almost 20% of patients over their average remaining lifetime. More than 80% of patients will cease treatment over that time, having likely experienced a deterioration of vision beforehand. This is a remarkable outcome compared with outcomes without intervention, which lead to legal blindness within 3 years of disease onset in 80% of those affected. These findings underline the public health necessity of providing anti-vascular endothelial growth factor treatment to persons in need.

Source:https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2771739
Like
Comment
Share